PRQR vs. MLYS, RNAC, LYEL, HROW, DNTH, ANNX, AVBP, LRMR, ZYME, and PHAT
Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Mineralys Therapeutics (MLYS), Cartesian Therapeutics (RNAC), Lyell Immunopharma (LYEL), Harrow (HROW), Dianthus Therapeutics (DNTH), Annexon (ANNX), ArriVent BioPharma (AVBP), Larimar Therapeutics (LRMR), Zymeworks (ZYME), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical preparations" industry.
ProQR Therapeutics (NASDAQ:PRQR) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.
ProQR Therapeutics presently has a consensus target price of $3.38, suggesting a potential upside of 82.43%. Mineralys Therapeutics has a consensus target price of $33.50, suggesting a potential upside of 154.95%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than ProQR Therapeutics.
32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Mineralys Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -260.75%. Mineralys Therapeutics' return on equity of -32.48% beat ProQR Therapeutics' return on equity.
ProQR Therapeutics received 316 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 61.74% of users gave ProQR Therapeutics an outperform vote.
In the previous week, ProQR Therapeutics had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 3 mentions for ProQR Therapeutics and 1 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.77 beat ProQR Therapeutics' score of -0.08 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
ProQR Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.
ProQR Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
Summary
ProQR Therapeutics and Mineralys Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get ProQR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProQR Therapeutics Competitors List
Related Companies and Tools
